A Case of Malignant Lymphomas that Healed Completely After Oral Administrations of 4-Hydroxybenzaldehyde
Journal Title: Open Access Journal of Oncology and Medicine - Year 2018, Vol 1, Issue 5
Abstract
In 1969, Mutsuyuki Kochi [1,2] developed 4-Hydroxybenzaldehyde for use as a novel anti-tumor agent without side effect and acquired its patent. Accordingly, this medicine is capable of preventing carcinogenesis when used in sufficient quantity. To treat advanced cancers, an oncologist should start with giving the cancer patient a small dose of the 4-Hydroxybenzaldehyde to avoid the possible severe hemorrhage of a tumor caused by excessive necrosis. Therefore, it has useful applications in treating lymphomas and leukemia’s. Consequently, those who have these diseases can receive a considerably large dose of the medicine. The mechanism of action of the medicine is apparently competitive inhibition of tyrosine kinase, which is the rate-limiting enzyme in the pathway of carcinogenesis [3,4]. A 45-year-old woman (Y.Y.) visited the author’s clinic on August 7, 2014. She said that she had been diagnosed to have a malignant lymphoma of 3cm-diameter at the right side of her clavicular cavity and another one of 1cm-diameter at the right side of her neck at Mitsuhashi Gynecological Clinic in Kohriyama City, Nara Prefecture on June 20, 2014. At the author’s clinic, she was prescribed with daily 83mg (17ml of 5mg/ml aqueous solution) of 4-Hydroxybenzaldehyde during the period from August 8, 2014 until December 8, 2014. The daily dose was raised to 111mg (22ml of 5mg/ml aqueous solution) during the period from December 9, 2014 until March 8, 2015. The daily dose was raised to 167mg (33ml of 5mg/ml aqueous solution) during the period from March 9, 2015 to May 13, 2015. The daily dose was raised to 222mg (44ml of 5mg/ml aqueous solution) during the period from May 14, 2015 to August 11, 2015. The daily dose was raised to 333mg (67ml of 5mg/ml aqueous solution) during the period from August 12, 2015 to September 13, 2015.
Authors and Affiliations
Kimihiko Okazaki
Keywords
Related Articles
- EP ID EP587885
- DOI 10.32474/OAJOM.2018.01.000124
- Views 76
- Downloads 0
Breast Cancer Screening in the United Arab Emirates: Is it Time to Call for a Screening at an Earlier Age?
Cancer is a major health issue around the world, in the United Arab Emirates ( UAE ) it is the 3rd leading cause of death after cardiovascular diseases and injuries, accounting for 10% of all mortalities in the UAE in 20...
Traditional Medicine in Contextual African Society: On-Going Challenges
The role of traditional medicine in contextual African society cannot be overemphasized. Due to the less financial implication on the part of patients(s) patronizing the medicine to treat a particular ailment. In recent...
Pilomatricoma Localized in the Arm: A Rare Case Report
A pilomatricoma is a rare, benign skin tumour originating from the hair follicle cells. It accounts for 0.15 of skin tumours is. It usually involves the head and neck region. The definitive diagnosis is based on histolog...
Colorectal Cancer in UAE, Implications on the Screening Program 2018
a) Colorectal cancer is the fourth (4th) common cancer in both sexes, worldwide and is the third most common cancer in men and the second in women. b) In 2012, 1.36 million cases of colorectal cancer occurred and there w...
Use of Umblical Cord Blood in the Management of Leukaemia
Leukaemia is a blood disorder caused by uncontrolled production and release of abnormal blasts cells in the bone marrow and in the circulation. Treatment of leukaemia has been a great challenge and many patients die. The...